Lyell Immunopharma
LYEL
LYEL
99 hedge funds and large institutions have $389M invested in Lyell Immunopharma in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 31 increasing their positions, 34 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
9% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 34
91% less call options, than puts
Call options by funds: $1K | Put options by funds: $11K
Holders
99
Holding in Top 10
3
Calls
$1K
Puts
$11K
Top Buyers
| 1 | +$13.3M | |
| 2 | +$13.1M | |
| 3 | +$2.37M | |
| 4 |
CGL
Clarius Group LLC
Seattle,
Washington
|
+$1.22M |
| 5 |
Swiss National Bank
Zurich,
Switzerland
|
+$864K |
Top Sellers
| 1 | -$5.57M | |
| 2 | -$4.94M | |
| 3 | -$1.24M | |
| 4 |
Two Sigma Investments
New York
|
-$1.05M |
| 5 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$954K |